PRESS RELEASE: Zosano Pharma Announces Funding Close Totaling $90 Million

Zosano Pharma Announces Funding Close Totaling $90 Million

FREMONT, Calif. -- Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products using innovative drug delivery, has announced the receipt of the second half of its initial venture funding of $45 million, for a total investment of $90 million. Four venture capital firms, New Enterprise Associates (NEA), Nomura Phase4 Ventures, HBM BioVentures and ProQuest Investments, participated in this final close.

“This second closing supports our continued progress with Zosano’s lead program, a PTH patch for treating osteoporosis, which is currently in Phase 2 development,” said Cory Zwerling, Zosano’s Chief Executive Officer. “Our PTH development program is on track and we are also moving other Zosano activities forward.”

Zosano's Macroflux® transdermal microprojection delivery system provides unique benefits, including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines. This transdermal system has been clinically tested in over 300 patients with four different peptides and a vaccine. Zosano’s PTH delivery system is in Phase 2 clinical trials and once approved, will be a treatment option for severely osteoporotic patients, along with other anabolic bone building agents.

“This funding strengthens Zosano, allowing us to focus on implementing our Phase 2 PTH program and other ongoing research activities,” said Zwerling. “With this focus on implementation, we are achieving our business goals and positioning Zosano for future successes.”

About Zosano Pharma, Inc.

Zosano Pharma, previously named The Macroflux Corporation, was founded in October 2006 as a Johnson and Johnson Internal Ventures spin-out from the ALZA Company to progress several product opportunities based on the company’s transdermal microprojection delivery system. Headquartered in new facilities in Fremont, California, Zosano Pharma currently has 44 employees. For further information, or to find out about licensing and partnering opportunities, visit www.zosanopharma.com.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.